[go: up one dir, main page]

KR20030024028A - treatment of avacular necrosis using VEGE transfected stem cells - Google Patents

treatment of avacular necrosis using VEGE transfected stem cells Download PDF

Info

Publication number
KR20030024028A
KR20030024028A KR1020010056977A KR20010056977A KR20030024028A KR 20030024028 A KR20030024028 A KR 20030024028A KR 1020010056977 A KR1020010056977 A KR 1020010056977A KR 20010056977 A KR20010056977 A KR 20010056977A KR 20030024028 A KR20030024028 A KR 20030024028A
Authority
KR
South Korea
Prior art keywords
treatment
necrosis
vege
stem cells
avacular
Prior art date
Application number
KR1020010056977A
Other languages
Korean (ko)
Inventor
하철원
Original Assignee
하철원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하철원 filed Critical 하철원
Priority to KR1020010056977A priority Critical patent/KR20030024028A/en
Publication of KR20030024028A publication Critical patent/KR20030024028A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

골조직의 무혈성 괴사의 치료를 위해 다양한 방법이 시도된바 있으나, 확실한 치료방법은 아직 정립되지 않은 상태이다.Various methods have been tried for the treatment of avascular necrosis of bone tissue, but a definite method of treatment has not yet been established.

본 고안은 줄기세포(mesenchmal stem cell)에 VEGE(혈관신생조절 유전자)를 vector를 이용하여 유전자 내에 삽입(transfection)한 상태로 무혈성골괴사의 부분에 주입하여 이부분에 다시 골조직의 생산을 유도하여 이 질환을 치료하는 것에 관한 것이다.The present invention injects VEGE (Angiogenesis Regulatory Gene) into a part of avascular bone necrosis while transfecting it into a gene using a vector and induces bone tissue production in this part. It is about treating a disease.

Description

혈관신생조절 유전자가 삽입된 줄기세포를 이용한 무혈성골괴사의 치료{treatment of avacular necrosis using VEGE transfected stem cells}Treatment of avascular bone necrosis using stem cells inserted with angiogenesis control genes {treatment of avacular necrosis using VEGE transfected stem cells}

무혈성 골괴사에 대해서는 다양한 치료방법이 있어 왔다.There have been various treatments for avascular bone necrosis.

기다려 보는 방법How to wait

핵감압술-진행이 매우 적게된 초기에만 적응됨Nuclear decompression-adapted only at very early stage

생비골이식술-수술술기가 매우 어렵고, 결과가 일정치 않고, 제공편에 질환을 남긴다.Live nasal transplantation-surgical procedures are very difficult, the results are inconsistent, and disease remains on the donor side.

인공관절치환술- 진행된 경우 최후의 치료법이며, 이는 향후 지속적인 추시 및 재치환술의 가능성이 항상 있으므로, 젊은 사람의 경우는 적응이 되기 어렵다.Artificial hip arthroplasty-It is the last treatment in advanced cases, and it is difficult to adapt to young people because of the possibility of continuous follow-up and revision.

최근 줄기세포를 이식한 경우가 있었으며, 이의 추시 결과는 아직 알려지지 않았고, 줄기세포가 골세포로 분화될지 혹은 근본적으로 혈관이 없는 조직내에서 세포가 살수 있을지는 아직 확인되지 않은 상태이다.In recent years, stem cells have been transplanted, and the results of the follow-up are not yet known, and it is not yet confirmed whether the stem cells will differentiate into bone cells or whether the cells can survive in tissues without blood vessels.

본 고안은 줄기세포의 유전자 내에 혈관신생을 조절하는 VEGE(혈관신생조절 유전자)를 transfection 하여 줄기세포가 골세포로 분화하면서 동시에 혈관의 신생을 유도하여 골조직의 재형성을 촉진하게 하는 것이다.The present invention is to transfect VEGE (Angiogenesis Regulatory Gene), which regulates angiogenesis in stem cell genes, to differentiate stem cells into bone cells and at the same time to induce angiogenesis and promote bone tissue remodeling.

VEGE(혈관신생조절 유전자)가 transfection된 줄기세포Stem cells transfected with VEGE

이를 무혈성골괴사부분에 삽입하여 골의 신생을 유도Insert it into avascular bone necrosis to induce bone formation

치료의 효과가 불명확하고, 정상적인 골조직으로의 치료가 어려운 무혈성괴사 부분을 정상적인 골조직으로 치료하여 그 효과가 일정하면서도 장기적일 수 있다.The effect of treatment is unclear, and treatment of avascular necrosis that is difficult to treat with normal bone tissue with normal bone tissue may have a constant and long-term effect.

Claims (1)

무혈성골괴사의 치료를 위한 VEGE(혈관신생조절 유전자)가 transfection된 줄기세포Stem Cells Transfected with VEGE (Angiogenesis Regulatory Gene) for Treatment of Avascular Necrosis
KR1020010056977A 2001-09-15 2001-09-15 treatment of avacular necrosis using VEGE transfected stem cells KR20030024028A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020010056977A KR20030024028A (en) 2001-09-15 2001-09-15 treatment of avacular necrosis using VEGE transfected stem cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020010056977A KR20030024028A (en) 2001-09-15 2001-09-15 treatment of avacular necrosis using VEGE transfected stem cells

Publications (1)

Publication Number Publication Date
KR20030024028A true KR20030024028A (en) 2003-03-26

Family

ID=27724132

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020010056977A KR20030024028A (en) 2001-09-15 2001-09-15 treatment of avacular necrosis using VEGE transfected stem cells

Country Status (1)

Country Link
KR (1) KR20030024028A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871199B2 (en) 2007-12-19 2014-10-28 Regenerative Sciences, Llc Compositions and methods to promote implantation and engrafment of stem cells
US9095562B2 (en) * 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
US9113950B2 (en) 2009-11-04 2015-08-25 Regenerative Sciences, Llc Therapeutic delivery device
US9133438B2 (en) 2011-06-29 2015-09-15 Biorestorative Therapies, Inc. Brown fat cell compositions and methods
US9168261B2 (en) 2008-03-14 2015-10-27 Regenerative Sciences, Llc Compositions and methods for cartilage repair
US11278573B2 (en) 2008-12-05 2022-03-22 Regenexx, LLC Methods and compositions to facilitate repair of avascular tissue

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095562B2 (en) * 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
US9700583B2 (en) 2007-07-05 2017-07-11 Regenerative Sciences, Llc Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
US8871199B2 (en) 2007-12-19 2014-10-28 Regenerative Sciences, Llc Compositions and methods to promote implantation and engrafment of stem cells
US9168261B2 (en) 2008-03-14 2015-10-27 Regenerative Sciences, Llc Compositions and methods for cartilage repair
US10898497B2 (en) 2008-03-14 2021-01-26 Regenexx, LLC Compositions and methods for cartilage repair
US11278573B2 (en) 2008-12-05 2022-03-22 Regenexx, LLC Methods and compositions to facilitate repair of avascular tissue
US9113950B2 (en) 2009-11-04 2015-08-25 Regenerative Sciences, Llc Therapeutic delivery device
US9133438B2 (en) 2011-06-29 2015-09-15 Biorestorative Therapies, Inc. Brown fat cell compositions and methods
US10597638B2 (en) 2011-06-29 2020-03-24 Biorestorative Therapies, Inc. Brown fat cell compositions and methods
US11066646B2 (en) 2011-06-29 2021-07-20 Biorestorative Therapies, Inc. Brown fat cell compositions and methods
US11851682B2 (en) 2011-06-29 2023-12-26 Biorestorative Therapies, Inc. Brown fat cell compositions and methods

Similar Documents

Publication Publication Date Title
BRPI0414455A (en) Methods for Using Regenerative Cells to Treat Peripheral Vascular Disease and Related Disorders
BR0212998A (en) Pluripotent stem cell produced and treated with a custom reprogramming agent; use thereof; and method for cell, organ or tissue production
CY1111106T1 (en) Anchoring for implantable heart valve prostheses
ATE375756T1 (en) IMPLANTABLE SLING
HK1102085A1 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
ZA907057B (en) Laser light irradiation apparatus
ATE237285T1 (en) MEDICAL IMPLANT
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
BR0112361A (en) Methods for treating inflammation-mediated eye conditions
ATE222511T1 (en) DEVICES FOR PROMOTING TISSUE GROWTH
ATE410982T1 (en) REGULATED DEVICE FOR THE TREATMENT OF HEARTBURN AND ACID REGULS
NO864254L (en) NEOVASCULARIZATION INHIBITORS AND PROCEDURES FOR THEIR PREPARATION AND USE.
Schultheiss et al. Rejuvenation in the early 20th century
ES8301616A1 (en) Vascular prostheses.
DK1274464T3 (en) Compositions and Methods for Regulating Protein Expression in the Intestine
KR20030024028A (en) treatment of avacular necrosis using VEGE transfected stem cells
Christ et al. The application of gene therapy to the treatment of erectile dysfunction
WO2004024089A3 (en) Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
DE60022478D1 (en) USE OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR FOR THE TREATMENT OF EFFECTIVE DYSFUNCTIONS
DE69727691D1 (en) USE OF KERATINOCYTEN GROWTH FACTOR-2
KR20030024027A (en) treatment of avacular necrosis using VEGE transfected osteocytes
Hendrich et al. Treatment of rheumatoid arthritis using photodynamic therapy
Arajy et al. Primary repair of unilateral cleft lip nasal deformity
Arslan LXV Ultrasonic Selective Hypophysectomy
RU2076649C1 (en) Method for treating coxarthrosis

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20010915

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid